Design of β-turn Based Therapeutic Agents

Title: Design of β-turn Based Therapeutic Agents

Volume: 9 Issue: 15

Author(s): K. Kee Suat and Seetharama D.S. Jois

Affiliation:

Keywords: proteins, peptidomimetics, amino acid, pharmacokinetics, melanocyte-stimulating hormone, bradykinin, lutenizing, circular dichroism(cd)

Abstract: Peptides and proteins are essential to many biological processes. The interaction between the peptide ligands and their receptor targets commonly involves β-turn structures. Yet poor bioavailability and unfavorable pharmacokinetics significantly compromise the use of peptides as drugs. Thus, there has been a great deal of interest in the design of peptidomimetics (modified peptides) as therapeutic agents by mimicking β-turn structures. This review highlights the importance of β-turn in the design of various peptidomimetics for many diseases. This review also outlines several β-turn mimicking strategies and its application in the design of potent peptide analogues. β-turn mimetics often tend to be more rigid in positioning the critically important amino acid residues and thus optimize the surface conformation for productive interaction with the receptors.

Cite this article as:

Suat Kee K. and Jois D.S. Seetharama, Design of β-turn Based Therapeutic Agents, Current Pharmaceutical Design 2003; 9 (15) . https://dx.doi.org/10.2174/1381612033454900